New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
05:55 EDTCBSH, CBSH, FRX, FRX, IRWD, IRWD, LEN, LEN, MBWM, MBWMCompanies reporting Before the Market Open on Tuesday
Notable companies reporting before the opening bell on Tuesday include Commerce Bancshares (CBSH), Forest Laboratories (FRX), Ironwood Pharmaceuticals (IRWD), Lennar Corp (LEN), and Mercantile Bank (MBWM).
News For CBSH;FRX;IRWD;LEN;MBWM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
10:01 EDTMBWMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:37 EDTMBWMMercantile Bank downgraded to Hold from Buy at Sandler O'Neill
Subscribe for More Information
07:38 EDTIRWDIronwood announces data from Phase I IW-1973 study
Ironwood Pharmaceuticals announced top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase stimulator. In the study, IW-1973 demonstrated cardiovascular pharmacodynamic effects, extensive tissue distribution, proof of mechanism for sGC stimulation, and a dose range that was well tolerated in healthy volunteers. The totality of clinical and preclinical data generated to date strongly support continued development of IW-1973 as a potential once-daily oral therapy. Ironwood intends to initiate a Phase Ib multiple ascending dose study of IW-1973 in the fourth quarter of 2015. This study will inform the selection of doses and priority indications for the Phase II program, which will focus on areas with the highest unmet need and optimal path to market. Ironwood intends to initiate at least two Phase II proof of concept studies for IW-1973 in 2016. The randomized, double-blind, placebo-controlled, single ascending dose Phase I study enrolled 46 healthy volunteers. Participants were randomized 3:1 to receive a single dose of IW-1973 or placebo administered via an oral capsule. Top-line clinical data were consistent with preclinical findings and included cardiovascular pharmacodynamic effects, dose-proportional pharmacokinetics, biomarker-based confirmation of target engagement, and evidence of extensive distribution to tissues. No serious adverse events were reported. Reported adverse events were consistent with the mechanism of action. Data from clinical and preclinical studies of IW-1973 are expected to be presented at a future medical conference.
July 21, 2015
06:05 EDTMBWMMercantile Bank reports Q2 EPS 39c, consensus 39c
Subscribe for More Information
06:00 EDTMBWMMercantile Bank raises dividend to 15c per share from 14c per share
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use